

LETTER TO THE EDITOR

NIPAH VIRUS PROPOSED VACCINES: ARE WE PREPARED FOR THE EXPECTED PANDEMIC?

ALUBAIDI G.T.

Medical research unit, College of Medicine, Al-Nahrain University, Baghdad, Iraq
E-mail: Ghasaqtariq119@gmail.com

Nipah virus is bat-borne paramyxovirus cause a zoonotic infection. Sever and often fatal encephalitis in human. Pigs are the intermediate hosts. Nipah virus represents a serious burden to the health sector; it usually records a high mortality rate reaching up to 75% [Tyagi S et al. 2025].

First outbreak was recorded in Malaysia in 1998-1999 involved pig-human transmission, caused 100 deaths and massive dissemination in swine reaching up to 1.1 million pigs, this represented about 40% of swine mass in Malaysia in 1999. Consequently, other outbreaks had been recorded in Asia; Singapore in 1999, 11 cases reported after pigs' importance from Malaysia. In India, the outbreaks occurs since 2001 till present, recently in 2026 two confirmed cases were reported. In Bangladesh outbreaks almost occur regularly since 1999 [Geisbert T et al. 2021].

Although the scenario is believed to be less aggressive comparing with that of COVID-19 as NiV is less contagious, the substantial fatality rate had driven the urgent need to develop an effective preventive strategy. Up to now no licensed vaccine to this virus has been launched, neither for human nor for pigs [Tyagi S et al. 2025].

Three pig-vaccines still under consideration; adjuvanted soluble G-protein, adjuvanted stabilized F protein and adenoviral vectored G protein (ChAdOx1-G). Immunological studies in pigs revealed that each vaccine elicited distinct immunogenicity profile. Prime dose of all three recorded high degree of protection with acceptable longevity. Such vaccines would protect if not prevent virus transmission to human, reducing socioeconomic consequence associated with expected outbreaks [McLean R et al. 2025].

Regarding human, four Nipa virus candidate vaccines are in the clinical trial-phase 1, usually

this phase include 20-100 healthy individuals. The live attenuated, vesicular stomatitis virus (VSV) -vectored, recombinant "rSVSA GEBOV-GP/NiV" and the adenoviral vector vaccine, ChAdOx1, both are viral vectored vaccine and both are ongoing in the clinical phase-I. A lipid nanoparticle- based messenger RNA vaccine, mRNA 1215, expressing viral glycoproteins, fusion protein (F – protein); and the attachment protein G of NiV was developed by Moderna in collaboration with Vaccine Research Center at NIAID is also in the ongoing in the 1st clinical trial. It mainly targets Malaysian strain Niv- M strain had completed in 2024 [Kim S et al. 2025, van Doremalen N et al. 2019].

A protein subunit vaccine, HeV-sGV, mapped out with aluminum hydroxide as adjuvant. Formulated by "Auro Vaccine LLC" in collaboration with "Program Appropriate Technology in health" and "Coalition for epidemic preparedness Innovation" has also been completed the phase-1 clinical trial. This proposed vaccine protects against Niv -Bangladesh and -Malaysian and the Hendra virus [Geisbert T et al. 2021].

Scholars, world-wide, identify those Asia-limited outbreaks as the tip of the iceberg and the seed from which future situation of outbreaks will evolve. Developing the aforementioned candidate vaccines make us one step closure to have NiV- approved vaccine.

REFERENCES

1. Tyagi S, Upadhyay S, Bharara T, Sahai S. Nipah virus: Preventing the next outbreak. World J Clin Cases. 2025 Apr 16;13(11). doi:10.12998/wjcc.v13.i11.99748
2. Geisbert TW, Bobb K, Borisevich V, Geisbert JB, Agans KN, Cross RW, et al. A single dose investigational subunit vaccine for human use

CITE THIS ARTICLE AS:

ALUBAIDI G.T. (2026). Nipah virus proposed vaccines: are we prepared for the expected pandemic?; The New Armenian Medical Journal, vol.20 (1), 119-120; DOI: <https://doi.org/10.56936/18290825-2026.20v.1-119>

- against Nipah virus and Hendra virus. *NPJ Vaccines*. 2021 Dec 1;6(1). doi:10.1038/s41541-021-00284-w PubMed PMID: 33558494.
3. McLean RK, Pedrera M, Thakur N, Elrefaey AME, Hodgson S, Lowther S, et al. Nipah virus vaccines evaluated in pigs as a 'One Health' approach to protect public health. *NPJ Vaccines*. 2025 Dec 1;10(1). doi:10.1038/s41541-025-01212-y
 4. Kim S, Kang H, Skrip L, Sahastrabuddhe S, Islam A, Jung SM, et al. Progress and challenges in Nipah vaccine development and licensure for epidemic preparedness and response. *Expert Rev Vaccines*. 2025;24(1):183–93. doi:10.1080/14760584.2025.2476523 PubMed PMID: 40047506.
 5. van Doremalen N, Lambe T, Sebastian S, Bushmaker T, Fischer R, Feldmann F, et al. A single-dose ChAdOx1-vectored vaccine provides complete protection against nipah Bangladesh and Malaysia in syrian golden hamsters. *PLoS Negl Trop Dis*. 2019 Jun 1;13(6). doi:10.1371/journal.pntd.0007462 PubMed PMID: 31170144.



CONTENTS

4. **ZILFYAN A.V., AVAGYAN S.A., MURADYAN A.A.**
HOW EFFECTIVE IS OUR “UNIVERSAL” RECEPTOR SYSTEM?
20. **BARKHUDARYAN A. L., CHILINGARYAN A. L., TUNYAN L. G.**
THE CURRENT STATE OF KNOWLEDGE ON THE MANAGEMENT OF ISCHEMIC HEART DISEASE IN PATIENTS WITH CANCER
34. **HARUTYUNYAN A. A., CHOPIKYAN A. S., GYULAZYAN N. M., MKHITARIAN M. H., SARGSYAN L. G., TADEVOSYAN A. E.**
FUNCTIONING OF MEDICAL INSTITUTIONS IN YEREVAN AND THE REGIONS OF ARMENIA DURING THE COVID-19 PANDEMIC
41. **TADEVOSYAN A. E., GYULAZYAN N. M., GHAZARYAN A.G., HOVHANNISYAN A.H., KARAPETYAN A.G., CHOPIKYAN A.S., HARUTYUNYAN A.A., MANUKYAN R.G., SARGSYAN L.G., MURADYAN A.A.**
SIGNIFICANCE OF SARS-COV-2 PCR POSITIVE AND NEGATIVE RESULTS IN THE CLINICAL COURSE AND LABORATORY PARAMETERS OF COVID-19
50. **AMR M.A.M., EL-SAYED MOHAMMAD H., ZAKI N.F., SOLIMAN A.A.A., AROCKIASAMY A.P.R.**
COGNITIVE PROFILES OF CHILDREN WITH ENCOPRESIS: INSIGHTS FROM THE STANFORD–BINET TEST
59. **AJDARI A., GHAEMI M.R., HOOSHMAND H., RADVAR M.**
EPIDEMIOLOGICAL CHARACTERISTICS AND COMORBIDITIES IN CHILDREN WITH ASTHMA
67. **ALAM A.R., MUSTARI M.N., LATIEF J., RASJAD C., BAUSAT A., ZAINUDDIN A.A., PRIHANTONO P., FARUK M.**
RELATIONSHIP BETWEEN SERUM TESTOSTERONE AND OSTEOPOROSIS IN OLDER MEN: A CROSS-SECTIONAL STUDY
74. **HOVHANNISYAN A.H., MANUKYAN S.G., MKHITARYAN S.L., KHACHATRYAN S.H., GYULAZYAN N.M., ASOYAN V.A.**
MULTIFOCAL OSTEOARTICULAR BRUCellosIS: A RARE CASE OF SPONDYLO-DISCITIS, VERTEBRAL ABSCESS, AND KNEE ARTHRITIS
81. **KREICBERGA I., REZEBERGA D., MISOVA A., VARDANYAN R., ARBUZOV G., TĒRVIDS T.**
COMPARISON OF RADIANT HEAT FLUX FROM A LARGE-SURFACE AND CONVENTIONAL NEONATAL WARMER USING STANDARDIZED BLACK BODY PLACEMENT
90. **KREICBERGA I., REZEBERGA D., MISOVA A., VARDANYAN R., ARBUZOV G., TĒRVIDS T.**
COMPARISON OF THERMAL CONDITIONS UNDER A COMMERCIAL NEONATAL RADIANT WARMER AND A NEWLY DEVELOPED LARGE-SURFACE RADIANT WARMER
102. **TANASHYAN M.M., RASKURAZHEV A.A., KUZNETSOVA P.I., SHABALINA A.A., PIRADOV M.A.**
ASPIRIN RESISTANCE IN PATIENTS WITH CEREBRAL ATHEROSCLEROSIS: POSSIBLE ROLE OF MICRORNAs
111. **KAKURINA G.V., SEREDA E.E., CHEREMISINA O.V., SIDENKO E.A., YUNUSOVA N.V., KORSHUNOV D.A., KONDAKOVA I.V., CHOYNZONOV E.L.**
THE RELATIONSHIP BETWEEN THE EXPRESSION ACTIVITY OF GENES ENCODING VIMENTIN AND ACTIN-BINDING PROTEINS IN PATIENTS WITH SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK WITH LYMPHOGENOUS METASTASIS.
119. **ALUBAIDI G.T. (LETTER TO THE EDITOR)**
NIPAH VIRUS PROPOSED VACCINES: ARE WE PREPARED FOR THE EXPECTED PANDEMIC?



The Journal is founded by
Yerevan State Medical
University after M. Heratsi.

Rector of YSMU

Armen A. *MURADYAN*

Address for correspondence:

Yerevan State Medical University
2 Koryun Street, Yerevan 0025,
Republic of Armenia

Phones:

(+37410) 582532 YSMU

(+37493) 588697 Editor-in-Chief

Fax: (+37410) 582532

E-mail: namj.ysmu@gmail.com, ysmiu@mail.ru

URL: <http://www.ysmu.am>

Our journal is registered in the databases of Scopus, EBSCO and Thomson Reuters (in the registration process)



SCOPUS



EBSCO



THE GUFO

Print in "Monoprint" LLC
Director: Armen Armenakyan
Andraniks St., 96/8 Bulding
Yerevan, 0064, Armenia
Phone: (+37491) 40 25 86
E-mail: monoprint1@mail.ru

TheGufo is an online database platform designed to help researchers publish and share their scientific work on a global scale. Our company was founded to address the need for an affordable and user-friendly platform that removes many of the barriers traditionally imposed by the publishing industry.

All scientific work published through TheGufo complies with Creative Commons 4.0 and other recognized standards to ensure authenticity, proper referencing, and academic integrity. Each submission undergoes a detailed peer-review process prior to publication.

Our mission is to provide researchers worldwide with a professional, accessible, and cost-effective platform to share both new and existing work with their peers. To further encourage participation, we also offer special promotional programs for academic institutions.

Dear reader, to access our website, please follow the link below
<https://thegufo.com/>

Editor-in-Chief

Arto V. *ZILFYAN* (Yerevan, Armenia)

Deputy Editors

Hovhannes M. *MANVELYAN* (Yerevan, Armenia)

Hamayak S. *SISAKYAN* (Yerevan, Armenia)

Executive Secretary

Stepan A. *AVAGYAN* (Yerevan, Armenia)

Editorial Board

Armen A. *MURADYAN* (Yerevan, Armenia)

Drastamat N. *KHUDAVERDYAN* (Yerevan, Armenia)

Suren A. *STEPANYAN* (Yerevan, Armenia)

Foregin Members of the Editorial Board

Waleed *GHANIMA* (Oslo, Norway)

Carsten N. *Gutt* (Memmingen, GERMAY)

Ming-Hua *ZHENG* (Wenzhou, China)

Coordinating Editor (for this number)

Farzad *KARIMPOUR* (Yasuj, IR Iran)

Editorial Advisory Council

Vahe Yu. *AZATYAN* (Yerevan, Armenia)

Ara S. *BABLOYAN* (Yerevan, Armenia)

Ines *BANJARI* (Osijek, Croatia)

Azat A. *ENGIBARYAN* (Yerevan, Armenia)

Mahdi *ESMAEILZADEH* (Mashhad, IR Iran)

Ruben V. *FANARJYAN* (Yerevan, Armenia)

Gabriele *FRAGASSO* (Milano, Italy)

Samvel G. *GALSTYAN* (Yerevan, Armenia)

Armen Dz. *HAMBARDZUMYAN* (Yerevan, Armenia)

Airazat M. *KAZARYAN* (Oslo, Norway)

Seyran P. *KOCHARYAN* (Yerevan, Armenia)

Levon M. *MKRTCHYAN* (Yerevan, Armenia)

Ashot M. *MKRTUMYAN* (MoscowRussia)

Mariam R *MOVSIYAN* (Gumri, Armenia)

Mikhail Z. *NARIMANYAN* (Yerevan, Armenia)

Sevak *SHAHBAZYAN* (Yerevan, Armenia)

Arthur K. *SHUKURYAN* (Yerevan, Armenia)

Gevorg N. *TAMAMYAN* (Yerevan, Armenia)

Marine M. *TANASHYAN* (Moscow, Russia)

Hakob V. *TOPCHYAN* (Yerevan, Armenia)

Alexander *WOODMAN* (London, England)

Konstantin B. *YENKOYAN* (Yerevan, Armenia)

Yumei *NIU* (Harbin, China)

Peijun *WANG* (Harbin, Chine)